---
title: "Rafael Holdings prioritizes Trappsol Cyclo development, CEO stepping down. TransportNPC Phase 3 trial fully enrolled, results in mid-2025."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237449772.md"
description: "The Phase 3 clinical trial of TransportNPC™ by Cyclo Therapeutics for treating Niemann-Pick Disease Type C1, a rare genetic condition, has completed enrollment. The trial is evaluating Trappsol® Cyclo™ and interim analysis results are anticipated in mid-2025 after 48 weeks of study. This marks a significant advancement in the research for this fatal disease."
datetime: "2025-04-24T20:37:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237449772.md)
  - [en](https://longbridge.com/en/news/237449772.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237449772.md)
generator: "portal-rs"
---

# Rafael Holdings prioritizes Trappsol Cyclo development, CEO stepping down. TransportNPC Phase 3 trial fully enrolled, results in mid-2025.

The Phase 3 clinical trial of TransportNPC™ by Cyclo Therapeutics for treating Niemann-Pick Disease Type C1, a rare genetic condition, has completed enrollment. The trial is evaluating Trappsol® Cyclo™ and interim analysis results are anticipated in mid-2025 after 48 weeks of study. This marks a significant advancement in the research for this fatal disease.

### Related Stocks

- [CYTH.US](https://longbridge.com/en/quote/CYTH.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**